Ikarian Capital »

Abbvie shares owned by Ikarian Capital

Quarter-by-quarter ownership of Abbvie (ABBV) shares owned by Ikarian Capital from 13F filings

Historical chart of Ikarian Capital investment in Abbvie

Tip: Access up to 7 years of quarterly data

All positions including Abbvie held by Ikarian Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Abbvie by Ikarian Capital

Quarter filed Position value Share count Share price at filing
2023-12-31 $21M 133k 154.97
2023-09-30 $20M 1.3k 14906.00
2020-03-31 $11M 150k 76.19

More positions owned by Ikarian Capital

Argenx Se Sponsored Adr (ARGX)
Krystal Biotech Call Option (KRYS)
Cytokinetics Com New (CYTK)
Alnylam Pharmaceuticals Call Option (ALNY)
Spdr Ser Tr S&p Biotech Put Option (XBI)
Crispr Therapeutics Namen Akt (CRSP)
Eli Lilly & Co. Put Option (LLY)
Sarepta Therapeutics (SRPT)
Prothena Corp SHS Call Option (PRTA)
Amylyx Pharmaceuticals (AMLX)
Nuvalent Inc-a (NUVL)
Immunovant (IMVT)
Crinetics Pharmaceuticals In (CRNX)
Soleno Therapeutics (SLNO)
Eyepoint Pharmaceuticals Com New (EYPT)

View all positions for Ikarian Capital

Top funds holding Abbvie

Vanguard Group
Jpmorgan Chase & Co
Charles Schwab Investment Management
Norges Bank Investment Management
Bank of America Corporation
Bank of New York Mellon
Legal & General Group
UBS Group
Goldman Sachs Group
Henderson Group
Wells Fargo & Company
T. Rowe Price Associates
Ubs Global Asset Management Americas
Royal Bank of Canada
Massachusetts Financial Services

View all funds holding Abbvie